Metabolism of 2′,3′-dideoxyinosine (ddI) in human blood.
Open Access
- 1 March 1992
- journal article
- Published by Wiley
- Vol. 33 (3) , 319-322
- https://doi.org/10.1111/j.1365-2125.1992.tb04043.x
Abstract
1. 2′,3′-Dideoxyinosine (ddI) has potent activity against human immunodeficiency virus (HIV). It is converted within target cells to its active form dideoxyadenosine triphosphate(ddA-TP). 2. In addition to the intracellular formation of ddA-TP, ddI can be broken down to hypoxanthine, by purine nucleoside phosphorylase (PNP) and to uric acid, by xanthine oxidase. Since PNP is present in red blood cells we have examined the metabolism of [14C]-ddI by human blood. 3. When incubated with whole blood at 37 degrees C, ddI was extensively metabolised, principally to hypoxanthine (50.4 +/- 12.5% formed at 6 h; mean +/- s.d.; n = 16). Small amounts of uric acid were formed (3.8 +/- 2.4%). 4. ddI breakdown was temperature dependent, being virtually negligible at 4 degrees C. Metabolism to hypoxanthine occurred within red blood cells. 5. The short half-life of ddI in patients is probably the result of both hepatic and erythrocytic metabolism.Keywords
This publication has 13 references indexed in Scilit:
- Overview of the Preclinical Development of an Antiretroviral Drug, 2′,3′-DideoxyinosineClinical Infectious Diseases, 1990
- 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related ComplexNew England Journal of Medicine, 1990
- High-performance liquid chromatographic method for analysis of 2′,3′-dideoxyinosine in human body fluidsJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolismClinica Chimica Acta; International Journal of Clinical Chemistry, 1988
- Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivityBiochemical Pharmacology, 1987
- Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivityBiochemical Pharmacology, 1987
- Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.Proceedings of the National Academy of Sciences, 1986
- [72] Purine nucleoside phosphorylase from human erythrocytesPublished by Elsevier ,1978
- INCORPORATION OF ANALOG PURINE NUCLEOSIDES INTO THE FORMED ELEMENTS OF HUMAN BLOOD: ERYTHROCYTES, PLATELETS, AND LYMPHOCYTES*Annals of the New York Academy of Sciences, 1975
- Purine nucleoside phosphorylase. VI. Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and speciesBiochemistry, 1975